In today’s briefing:
- Healthcare Global (HCG): Beyond Consolidation Now, Next Two Years Could Be Strong
- Cloudbreak (拨康视云) Pre-IPO: PHIP Updates
- How Roivant Sciences Could Score Big Wins Through High-Stakes IP Battles with Pharma Giants!
- Siemens Healthineers: Can Photon Counting CT Spark the Next Imaging Revolution?
- Takeover Doubts Grow: Break-Up Value Still Supports Re-Rating Case
- SunMoon Food’s Zhang Ye Boosts Interests
- SK Bioscience (302440 KS): Dual Engines Led Growth Strategy Is on Track; Solid 1Q25 Performance
- Hybridan Research: Physiomics plc: Synergistic Services
Healthcare Global (HCG): Beyond Consolidation Now, Next Two Years Could Be Strong
- HCG continues to scale up well with the emerging centers reporting 32% YoY revenue growth in Q4FY25. Q4FY25 revenue from established centers also grew strong at 22% YoY.
- International footfalls have resumed strong, led by which the revenue in the South Mumbai center grew 38% YoY. Revenue in Kolkata center also grew well at 22% YoY.
- HCG has been in consolidation phase over the last four years. Now, the next two years should witness strong growth in profitability, led by margin expansion and continued volume growth.
Cloudbreak (拨康视云) Pre-IPO: PHIP Updates
- Cloudbreak re-filed for a Hong Kong listing to raise at least USD 100 million.
- In this note, we look at updates to the prospectus. We noted delays in its products and downward revisions of prospects.
- We checked peer performance and have a negative readthrough for the company.
How Roivant Sciences Could Score Big Wins Through High-Stakes IP Battles with Pharma Giants!
- Roivant Sciences, in its most recent fiscal year-end earnings, reported a period of significant activity and progress across several fronts.
- The company emphasized advancements in its late-stage pipeline, particularly in its anti-FcRn franchise and developments in brepocitinib.
- The fiscal year was marked by the generation of critical data from studies involving batoclimab in Myasthenia Gravis and CIDP, as well as anticipation for pivotal data from brepocitinib in dermatomyositis, which could lead to novel treatments with significant lead-time advantages.
Siemens Healthineers: Can Photon Counting CT Spark the Next Imaging Revolution?
- Siemens Healthineers presented a mixed report for the second quarter of fiscal 2025, underscoring both favorable growth trajectories and certain market headwinds.
- The company reported nearly 7% revenue growth, outpacing its full-year guidance.
- This top-line expansion was combined with margin improvements, leading to an increase in adjusted EPS.
Takeover Doubts Grow: Break-Up Value Still Supports Re-Rating Case
- Gerresheimer trades at a steep discount to peers despite premium drug delivery exposure.
- A €70/share offer aligns with DCF fair value and the upper end of SOTP estimates.
- Divesting glass, lowering leverage, and PE-led reform could unlock 50–80% upside.
SunMoon Food’s Zhang Ye Boosts Interests
- Institutions recorded a net outflow of S$42 million from Singapore stocks from June 13 to June 18, 2025.
- Singapore Telecommunications led 2Q25 net institutional inflows with S$1.6 billion, increasing its Straits Times Index weight.
- DBS Group Holdings, United Overseas Bank, and Oversea-Chinese Banking Corporation led share buybacks totaling S$58.9 million.
SK Bioscience (302440 KS): Dual Engines Led Growth Strategy Is on Track; Solid 1Q25 Performance
- SK Bioscience (302440 KS) has initiated global Phase 3 clinical trial of GBP410, a 21-valent pneumococcal conjugate vaccine (PCV21) candidate, with topline result expected in 2027.
- IDT Biologika recorded revenue of KRW118B in 1Q25, up from KRW111B in 4Q24. Considering 1Q25 momentum, IDT seems to be on track to meet 2025 guidance of KRW410B.
- 1Q25 base business revenue increased 62% YoY to KRW36B. Operating loss of the base business narrowed to KRW26B from a loss of KRW28B in year-ago quarter.
Hybridan Research: Physiomics plc: Synergistic Services
- A further two contracts worth a combined £111,000 were announced this morning by the Company, as the total revenue pipeline continues to build.
- These contracts with a new UK-based biopharmaceutical client have been won by the recently established Biometrics services division.
- The Physiomics team have delivered over 100 commercial projects for drug development clients, including but not limited to, Merck KGaA, Astellas, Bicycle Therapeutics, Numab Therapeutics and Cancer Research UK.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Data and News
- ✓ Events & Webinars
